Towards a quantitative representation of the cell signaling mechanisms of hallucinogens: Measurement and mathematical modeling of 5-HT1A and 5-HT2A receptor-mediated ERK1/2 activation

被引:20
作者
Chang, Chiung-wen [1 ]
Poteet, Ethan [3 ]
Schetz, John A. [3 ]
Gumus, Zeynep H. [1 ,2 ]
Weinstein, Harel [1 ,2 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, HRH Price Alwaleed Bin Talal Bin Abdulaziz Alsaud, New York, NY 10021 USA
[3] Univ N Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA
关键词
Computational simulations of signaling pathways; G protein coupled receptors; Systems biology; Receptors of hallucinogenic drugs of abuse; Serotonin receptors; MAPK phosphorylation cascade; PROTEIN-KINASE ACTIVATION; ARACHIDONIC-ACID; COUPLED RECEPTORS; MOLECULAR-BASIS; SEROTONIN; DYNAMICS; COMPLEX; BINDING; PATHWAYS; BIOLOGY;
D O I
10.1016/j.neuropharm.2008.07.049
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Through a multidisciplinary approach involving experimental and computational studies, we address quantitative aspects of signaling mechanisms triggered in the cell by the receptor targets of hallucinogenic drugs, the serotonin 5-HT2A receptors. To reveal the properties of the signaling pathways, and the way in which responses elicited through these receptors alone and in combination with other serotonin receptors' subtypes (the 5-HT1AR), we developed a detailed mathematical model of receptor-mediated ERK-1/2 activation in cells expressing the 5-HT1A and 5-HT2A subtypes individually, and together. In parallel, we measured experimentally the activation of ERK1/2 by the action of selective agonists on these receptors expressed in HEK293 cells. We show here that the 5-HT1AR agonist Xaliproden HCl elicited transient activation of ERK-1/2 by phosphorylation, whereas 5-HT2AR activation by TCB-2 led to higher, and more sustained responses. The 5-HT2AR response dominated the MAPK signaling pathway when co-expressed with 5-HT1AR, and diminution of the response by the 5-HT2AR antagonist Ketanserin could not be rescued by the 5-HT1AR agonist. Computational simulations produced qualitative results in good agreement with these experimental data, and parameter optimization made this agreement quantitative. In silico simulation experiments suggest that the deletion of the positive regulators PKC in the 5-HT2AR pathway, or PLA2 in the combined 5-HT1A/2AR model greatly decreased the basal level of active ERK1/2. Deletion of negative regulators of MKP and PP2A in 5-HT1AR and 5-HT2AR models was found to have even stronger effects. Under various parameter sets, simulation results implied that the extent of constitutive activity in a particular tissue and the specific drug efficacy properties may determine the distinct dynamics of the 5-HT receptor-mediated ERK1/2 activation pathways. Thus, the mathematical models are useful exploratory tools in the ongoing efforts to establish a mechanistic understanding and an experimentally testable representation of hallucinogen-specific signaling in the cellular machinery, and can be refined with quantitative, function-related information. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:213 / 225
页数:13
相关论文
共 74 条
[1]   Molecular psychology: Roles for the ERK MAP kinase cascade in memory [J].
Adams, JP ;
Sweatt, JD .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2002, 42 :135-163
[2]   Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells [J].
Adayev, T ;
El-Sherif, Y ;
Barua, M ;
Penington, NJ ;
Banerjee, P .
JOURNAL OF NEUROCHEMISTRY, 1999, 72 (04) :1489-1496
[3]  
Aghajanian GK, 1999, NEUROPSYCHOPHARMACOL, V21, pS16
[4]   PHARMACOLOGICALLY DISTINCT ACTIONS OF SEROTONIN ON SINGLE PYRAMIDAL NEURONS OF THE RAT HIPPOCAMPUS RECORDED INVITRO [J].
ANDRADE, R ;
NICOLL, RA .
JOURNAL OF PHYSIOLOGY-LONDON, 1987, 394 :99-124
[5]  
Berg KA, 1996, MOL PHARMACOL, V50, P1017
[6]   MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network [J].
Bhalla, US ;
Ram, PT ;
Iyengar, R .
SCIENCE, 2002, 297 (5583) :1018-1023
[7]  
Bock G.R., 2002, NOVARTIS FDN S, V247, P270
[8]  
BODDEKE HWGM, 1992, N-S ARCH PHARMACOL, V345, P257
[9]  
CAMPAGNE F, 2004, SCI STKE, P111
[10]   Mammalian MAP kinase signalling cascades [J].
Chang, LF ;
Karin, M .
NATURE, 2001, 410 (6824) :37-40